Gagnon Securities LLC Has $19.39 Million Holdings in Intuitive Surgical, Inc. $ISRG

Gagnon Securities LLC reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 19.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 43,359 shares of the medical equipment provider’s stock after selling 10,465 shares during the period. Intuitive Surgical comprises approximately 3.9% of Gagnon Securities LLC’s investment portfolio, making the stock its 7th largest position. Gagnon Securities LLC’s holdings in Intuitive Surgical were worth $19,391,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Strategic Advisors LLC grew its stake in shares of Intuitive Surgical by 63.3% during the third quarter. Strategic Advisors LLC now owns 10,397 shares of the medical equipment provider’s stock worth $4,650,000 after buying an additional 4,031 shares during the last quarter. AE Wealth Management LLC lifted its stake in shares of Intuitive Surgical by 18.9% in the 3rd quarter. AE Wealth Management LLC now owns 11,556 shares of the medical equipment provider’s stock valued at $5,168,000 after acquiring an additional 1,836 shares during the last quarter. LRI Investments LLC boosted its holdings in shares of Intuitive Surgical by 24.0% during the 3rd quarter. LRI Investments LLC now owns 1,997 shares of the medical equipment provider’s stock valued at $893,000 after acquiring an additional 387 shares in the last quarter. Birchbrook Inc. grew its position in Intuitive Surgical by 5.1% during the 3rd quarter. Birchbrook Inc. now owns 1,533 shares of the medical equipment provider’s stock worth $686,000 after acquiring an additional 74 shares during the last quarter. Finally, Activest Wealth Management increased its holdings in Intuitive Surgical by 21.7% in the 3rd quarter. Activest Wealth Management now owns 112 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 20 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Robert W. Baird cut their price target on Intuitive Surgical from $655.00 to $645.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Piper Sandler reiterated an “overweight” rating and set a $620.00 target price (up from $610.00) on shares of Intuitive Surgical in a research report on Friday, January 23rd. Raymond James Financial boosted their target price on shares of Intuitive Surgical from $603.00 to $615.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. UBS Group reaffirmed a “neutral” rating on shares of Intuitive Surgical in a research note on Thursday, January 15th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Intuitive Surgical in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $620.41.

Insider Buying and Selling

In other Intuitive Surgical news, SVP Mark Brosius sold 4,500 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $547.36, for a total value of $2,463,120.00. Following the transaction, the senior vice president directly owned 907 shares of the company’s stock, valued at approximately $496,455.52. The trade was a 83.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Henry L. Charlton sold 13,731 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $580.00, for a total value of $7,963,980.00. Following the transaction, the executive vice president owned 3,056 shares in the company, valued at $1,772,480. The trade was a 81.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 75,557 shares of company stock worth $42,000,903 over the last three months. Insiders own 0.70% of the company’s stock.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: FDA clearance expands the da Vinci 5 indication set into select advanced cardiac procedures — large addressable‑market implication and a long‑term revenue tail for systems and consumables. Read More.
• Positive Sentiment: TD Cowen initiated/raised coverage to a strong‑buy, which can attract institutional demand and support near‑term buying interest. Read More.
• Positive Sentiment: Major sell‑side support continues (Barclays reaffirmed buy) and HSBC issued a bullish price‑appreciation forecast — both reinforce positive analyst momentum around growth prospects. Read More. Read More.
• Positive Sentiment: Active managers (Polen Capital) are highlighting ISRG as a core growth holding, signaling conviction from long‑term growth investors. Read More.
• Neutral Sentiment: Analysts are split on valuation — some price‑target trims (e.g., Evercore ISI) coexist with higher targets from other firms; that creates mixed guidance for short‑term price direction. Read More.
• Neutral Sentiment: Coverage pieces questioning whether to “reassess” ISRG after recent share weakness may drive flows from momentum or value‑oriented investors, but they’re not direct catalysts. Read More.
• Negative Sentiment: Significant insider selling by director Gary S. Guthart (24,500 shares + 2,800 shares disclosed) — large, disclosed sales can trigger profit‑taking and amplify downward pressure on the stock near term. Read More.
• Negative Sentiment: EVP Myriam Curet sold 230 shares (smaller amount) — adds to the day’s insider activity and can increase negative sentiment despite being immaterial in size. Read More.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $507.55 on Friday. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $609.08. The firm’s fifty day moving average is $559.78 and its 200-day moving average is $511.72. The firm has a market cap of $181.95 billion, a P/E ratio of 64.33, a P/E/G ratio of 4.05 and a beta of 1.67.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.26. The business had revenue of $2.87 billion for the quarter, compared to analyst estimates of $2.72 billion. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. Intuitive Surgical’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.21 earnings per share. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.